Literature DB >> 29297100

Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis.

Shuling Li1, Doyt L Conn2, Athan Tiliakos3, Gaobin Bao3, Kirk A Easley4.   

Abstract

Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry. In a prospective, multicenter observational cohort study, AA with early RA were enrolled and followed longitudinally for up to 5 years. 345 were enrolled. The mean age at enrollment was 51 years and 82% were women. At baseline, the prevalence of low dose prednisone use was 77% and median prednisone dose was 10 mg. At enrollment 238 patients were on single daily and 107 on divided daily doses of prednisone. There was a significant reduction during follow-up in the number of tender and swollen joints and in the HAQ scores in all patients. Cohort retention was 54%. The adjusted mean number of tender joints was approximately 2-3 joints lower for patients on divided daily dose compared to a single daily dose in follow up. The rate of osteopenia and osteoporosis at 5 years remained similar to baseline prevalence and no difference in the treatment groups. At 5 years the percentage of patients with hypertension was lower in the divided daily prednisone group. During the 5 years of follow-up, clinical outcomes improved in all AA patients with early RA. Reduced number of tender joints was associated with divided daily low doses of prednisone. Hypertension was less in those treated with divided daily doses of prednisone.

Entities:  

Keywords:  African Americans; Early rheumatoid arthritis; Low dose prednisone

Mesh:

Substances:

Year:  2018        PMID: 29297100     DOI: 10.1007/s10067-017-3943-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

Review 1.  Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management.

Authors:  Rainer H Straub; Maurizio Cutolo
Journal:  Arthritis Rheum       Date:  2007-02

2.  Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.

Authors:  J L Barton; L Trupin; D Schillinger; S A Gansky; C Tonner; M Margaretten; V Chernitskiy; J Graf; J Imboden; E Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Authors:  Marije F Bakker; Johannes W G Jacobs; Paco M J Welsing; Suzanne M M Verstappen; Janneke Tekstra; Evelien Ton; Monique A W Geurts; Jacobine H van der Werf; Grietje A van Albada-Kuipers; Zalima N Jahangier-de Veen; Maaike J van der Veen; Catharina M Verhoef; Floris P J G Lafeber; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

5.  Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline.

Authors:  Loreto Massardo; Bernardo A Pons-Estel; Daniel Wojdyla; Mario H Cardiel; Claudio M Galarza-Maldonado; Mónica P Sacnun; Enrique R Soriano; Ieda M Laurindo; Eduardo M Acevedo-Vásquez; Carlo V Caballero-Uribe; Oslando Padilla; Zoila M Guibert-Toledano; Licia M da Mota; Rubén A Montufar; Leticia Lino-Pérez; José F Díaz-Coto; Angel F Achurra-Castillo; Jaime A Hernández; María H Esteva-Spinetti; Luis A Ramírez; Carlos Pineda; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

6.  The timing of glucocorticoid administration in rheumatoid arthritis.

Authors:  N G Arvidson; B Gudbjörnsson; A Larsson; R Hällgren
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

7.  Does a family history of RA influence the clinical presentation and treatment response in RA?

Authors:  Thomas Frisell; Saedis Saevarsdottir; Johan Askling
Journal:  Ann Rheum Dis       Date:  2015-06-19       Impact factor: 19.103

8.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

9.  Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs.

Authors:  Mary Chester Wasko; Abhijit Dasgupta; Genevieve Ilse Sears; James F Fries; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-05       Impact factor: 4.794

10.  Comparison between women and men with recent onset rheumatoid arthritis of disease activity and functional ability over two years (the TIRA project).

Authors:  E Hallert; I Thyberg; U Hass; E Skargren; T Skogh
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.